Sequential Stem Cell–Kidney Transplantation in Schimke Immuno-osseous Dysplasia

  • Bertaina A
  • Grimm P
  • Weinberg K
  • et al.
17Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune rejection and the need for post-transplantation immunosuppression in three patients with Schimke immuno-osseous dysplasia who had both T-cell immunodeficiency and renal failure. Each patient received sequential transplants of αβ T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney from the same donor. Full donor hematopoietic chimerism and functional ex vivo T-cell tolerance was achieved, and the patients continued to have normal renal function without immunosuppression at 22 to 34 months after kidney transplantation. (Funded by the Kruzn for a Kure Foundation.).

Cite

CITATION STYLE

APA

Bertaina, A., Grimm, P. C., Weinberg, K., Parkman, R., Kristovich, K. M., Barbarito, G., … Lewis, D. B. (2022). Sequential Stem Cell–Kidney Transplantation in Schimke Immuno-osseous Dysplasia. New England Journal of Medicine, 386(24), 2295–2302. https://doi.org/10.1056/nejmoa2117028

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free